Pro-Dex, Inc. (NASDAQ:PDEX – Get Rating)'s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.27 and traded as high as $17.99. Pro-Dex shares last traded at $17.48, with a volume of 2,397 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Pro-Dex in a report on Wednesday, December 7th. They set a "hold" rating for the company.
Get Pro-Dex alerts:Pro-Dex Stock Performance
The firm has a market capitalization of $62.58 million, a price-to-earnings ratio of 16.81 and a beta of 0.91. The company has a fifty day moving average of $18.11 and a two-hundred day moving average of $17.27. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.39 and a current ratio of 2.73.
Institutional Trading of Pro-Dex
Several hedge funds have recently added to or reduced their stakes in PDEX. Tower Research Capital LLC TRC raised its holdings in Pro-Dex by 345.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock valued at $48,000 after acquiring an additional 2,084 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Pro-Dex in the 2nd quarter valued at $168,000. State Street Corp raised its holdings in Pro-Dex by 5.8% in the 1st quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock valued at $197,000 after acquiring an additional 650 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Pro-Dex by 59.2% in the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock valued at $345,000 after acquiring an additional 7,762 shares in the last quarter. Finally, LSV Asset Management raised its holdings in Pro-Dex by 13.9% in the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock valued at $588,000 after acquiring an additional 4,346 shares in the last quarter. 13.69% of the stock is owned by institutional investors and hedge funds.Pro-Dex Company Profile
(Get Rating)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- NVIDIA vs AMD: Which is better for 2023?
- Can FDA Approval Bolster DexCom, Inc.?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.